Guardant Health Inc. (GH)
Guardant Health Sees Shield, MRD and Oncology Testing Growth Accelerate
Guardant Health NASDAQ: GH highlighted growth across its oncology testing, minimal residual disease, and colorectal cancer screening businesses at the Canaccord Genuity Growth Conference, with co-CEOs Helmy Eltoukhy and AmirAli Talasaz pointing to expanding adoption, new reimbursement developments, and planned product launches.
Guardant Health, Inc. (GH) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript
Guardant Health, Inc. (GH) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript
Guardant Health: Screening And MRD Are Just Getting Started
Guardant Health is experiencing robust growth, driven by its MRD and screening businesses. Recent FDA approvals, expanded reimbursement, and inclusion in clinical guidelines should help to ensure growth remains strong going forward. Competition in both screening and MRD monitoring is set to intensify in coming years, though.
Guardant Health, Inc. (GH) Q2 2026 Earnings Call Transcript
Guardant Health, Inc. (GH) Q2 2026 Earnings Call Transcript
Guardant Health (GH) Reports Q2 Loss, Tops Revenue Estimates
Guardant Health (GH) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.4. This compares to a loss of $0.44 per share a year ago.
Guardant Health (GH) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for Guardant Health (GH) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Wall Street's Insights Into Key Metrics Ahead of Guardant Health (GH) Q2 Earnings
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Guardant Health (GH), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2026.
Guardant Health (GH) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Guardant Health (GH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Guardant Health, Inc. (GH) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Guardant Health, Inc. (GH) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Guardant Health, Inc. (GH) Q1 2026 Earnings Call Transcript
Guardant Health, Inc. (GH) Q1 2026 Earnings Call Transcript
Compared to Estimates, Guardant Health (GH) Q1 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Guardant Health (GH) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Guardant Health (GH) Reports Q1 Loss, Beats Revenue Estimates
Guardant Health (GH) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to a loss of $0.49 per share a year ago.
